Amarin Stays Rangebound, Prescriptions Stagnate (ProactiveInvestors)
Amarin Corporation plc (ADR) (NASDAQ:AMRN) has been struggling a lot lately as retail channel prescription data for its EPA capsule Vascepa imply that the drug is starting to slow down its momentum in the MARINE indication (hypertriglyceridemia patients with >500 mg/dL). While the company has seen significant progress since the launch of the drug in January, it is still not causing any excitement in an investor base that wanted to see a big pharma buyout of the company ever since the company reported successful Phase III results. Despite the incredible strength of the broader market and the biotech sector in particular this year, AMRN is down 14% YTD as of the time of writing.
Big Pharma Wants Fish Oil After All, But At Half Amarin’s Selling Price (TheStreet)
Big Pharma is interested in prescription-grade fish oil after all. AstraZeneca plc (NYSE:AZN) is buying Omthera Pharmaceuticals Inc (NASDAQ:OMTH) in an incentive-laden deal worth up to $443 million. To buy Omthera Pharmaceuticals Inc (NASDAQ:OMTH), AstraZeneca plc (NYSE:AZN) passed over Amarin Corporation plc (ADR) (NASDAQ:AMRN) and its prescription-grade fish oil Vascepa. Perhaps Amarin will also find a Big Pharma buyer one day, except the market value for its only product has now been set at roughly half the company’s current $1 billion market valuation. Looks like Amarin Corporation plc (ADR) (NASDAQ:AMRN) can be bought for $4 per share. Any takers?
Amarin (AMRN) Sees Upside After AstraZeneca Scoops-Up Omthera (OMTH) (StreetInsider)
Amarin Corporation plc (ADR) (NASDAQ:AMRN) is seeing pre-open interest Tuesday after AstraZeneca plc (NYSE:AZN) acquired fellow fish oil pharmaceutical company Omthera Pharmaceuticals Inc (NASDAQ:OMTH) for as much as $443 million. While the comparable valuation of the deal is not viewed as positive for Amarin Corporation plc (ADR) (NASDAQ:AMRN), speculators suggest the deal activity puts the spotlight directly on Amarin. Shares of Amarin Corporation plc (ADR) (NASDAQ:AMRN) last traded at $7.05, up 4 percent.
Amarin Corporation plc (ADR) : Amarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin Therapy (4-Traders)
Amarin Corporation plc (ADR) (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s U.S. Patent Application Serial Number 13/417,899 titled “Pharmaceutical Compositions Comprising EPA and a Cardiovascular Agent and Methods of Using the Same.” This application includes claims intended to protect the Vascepa® (icosapent ethyl) indication approved by the U.S. Food and Drug Administration (FDA) based on Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s MARINE clinical trial results specifically those results seen in patients on statin therapy.